Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 21, 2011Clinical Cancer Research

New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

GOGeoffrey R. OxnardBoston Medical CenterMAMaria E. ArcilaNorthside HospitalJCJuliann ChmieleckiAstraZeneca (United States)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Oxnard et al. (2011) studied this question.

synapsesocial.com/papers/6a75ee6cf56d87d9178b7398https://doi.org/10.1158/1078-0432.ccr-10-2571
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer2009 · 795 citations
  2. 2Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer2010 · 430 citations
  3. 3Noninvasive Detection of <i>EGFR</i> T790M in Gefitinib or Erlotinib Resistant Non–Small Cell Lung Cancer2009 · 229 citations
  4. 4Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors2011 · 3,605 citations